Home » Stocks » MBIO

Mustang Bio, Inc. (MBIO)

Stock Price: $4.93 USD 0.22 (4.67%)
Updated Jan 20, 2021 4:00 PM EST - Market closed
After-hours: $5.10 +0.17 (3.45%) Jan 20, 7:55 PM
Market Cap 312.88M
Revenue (ttm) -50,000
Net Income (ttm) -55.62M
Shares Out 57.25M
EPS (ttm) -1.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 20
Last Price $4.93
Previous Close $4.71
Change ($) 0.22
Change (%) 4.67%
Day's Open 4.88
Day's Range 4.67 - 5.12
Day's Volume 5,397,302
52-Week Range 1.91 - 5.12

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 1 day ago

Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.

Other stocks mentioned: CAIXY, CLVS, DHT, OPK, RNWK, RYCEY
GlobeNewsWire - 2 weeks ago

WORCESTER, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthrough...

Benzinga - 3 weeks ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: FL, GME, NTAP, ARVN, BCAB, COUP, EOSE, GWRE, JKHY, ODT, UPST, VST
GlobeNewsWire - 1 month ago

Data presented at the 62 nd American Society of Hematology (ASH) Annual Meeting show extremely favorable safety profile and clinical activity

Zacks Investment Research - 1 month ago

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

GlobeNewsWire - 1 month ago

Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST Call to be held Wednesday, December 9, 2020, at 1:00 p.m. EST

GlobeNewsWire - 1 month ago

WORCESTER, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthrough...

GlobeNewsWire - 2 months ago

WORCESTER, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthrough...

GlobeNewsWire - 2 months ago

WORCESTER, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today's medical breakthrough...

InvestorPlace - 2 months ago

Biotech stocks are always going to be here, in good times and bad. Let's look at a few that are worth considering on the long side.

Other stocks mentioned: ABBV, AMGN, BLUE, BMY, REGN, VRTX
GlobeNewsWire - 2 months ago

Data presented by City of Hope at 27th Annual Prostate Cancer Foundation Scientific Retreat Data presented by City of Hope at 27th Annual Prostate Cancer Foundation Scientific Retreat

GlobeNewsWire - 3 months ago

WORCESTER, Mass., Oct. 08, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthrough...

GlobeNewsWire - 3 months ago

Mustang to leverage LentiBOOST™ for the development of MB-207 lentiviral gene therapy Mustang to leverage LentiBOOST™ for the development of MB-207 lentiviral gene therapy

GlobeNewsWire - 3 months ago

WORCESTER, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthrough...

GlobeNewsWire - 3 months ago

WORCESTER, Mass., Sept. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthro...

Zacks Investment Research - 4 months ago

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

GlobeNewsWire - 4 months ago

WORCESTER, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthrou...

Seeking Alpha - 4 months ago

Mustang Bio: Slow, Steady Progress Towards Multiple Gene And CAR-T Therapy Goals

Zacks Investment Research - 5 months ago

Investors need to pay close attention to Mustang Bio (MBIO) stock based on the movements in the options market lately.

GlobeNewsWire - 5 months ago

WORCESTER, Mass., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthrou...

GlobeNewsWire - 5 months ago

WORCESTER, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthrou...

Zacks Investment Research - 5 months ago

Mustang Bio (MBIO) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Benzinga - 7 months ago

Mustang Bio, Inc. (NASDAQ: MBIO) shares are trading lower after the company announced a common stock offering of 10.769 million shares at $3.25 per share.

Zacks Investment Research - 7 months ago

Mustang Bio (MBIO) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

WORCESTER, Mass., June 10, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthrou...

Zacks Investment Research - 7 months ago

Mustang (MBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

GlobeNewsWire - 9 months ago

NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in ...

GlobeNewsWire - 11 months ago

The subject achieved a complete response The subject achieved a complete response

GlobeNewsWire - 11 months ago

NEW YORK, Jan. 22, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in c...

Zacks Investment Research - 1 year ago

Mustang Bio, Inc. (MBIO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Benzinga - 1 year ago

The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida.

Other stocks mentioned: DTIL, FTSV, RHHBY, TGTX
ETF Trends - 1 year ago

As investors consider the current market conditions today, many should be prepared for what is coming and how looking beyond the benchmark through customized ETF strategies may help diversify ...

Other stocks mentioned: DIAL, RECS, REVS
GlobeNewsWire - 1 year ago

First dose occurred in trial currently underway at the University of Alabama at Birmingham First dose occurred in trial currently underway at the University of Alabama at Birmingham

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in ...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in ...

GlobeNewsWire - 1 year ago

NEW YORK, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in ...

GlobeNewsWire - 1 year ago

RMAT designation follows positive Phase 1/2 clinical data published in the New England Journal of Medicine

Seeking Alpha - 1 year ago

Mustang Bio presented positive data from a phase 1/2 study using MB-107 to treat patients with a rare disease known as X-linked severe combined immunodeficiency.

Seeking Alpha - 1 year ago

Mustang Bio, Inc. soared last Thursday after the very successful results of its gene therapy.

Other stocks mentioned: FBIO
The Motley Fool - 1 year ago

A new gene therapy could be a functional cure for "bubble boy" disease.

24/7 Wall Street - 1 year ago

Mustang Bio Inc. shares more than tripled on Thursday after the company announced a breakthrough that cured eight infants dealing with the “Bubble Boy” immune disorder.

Benzinga - 1 year ago

Shares of Mustang Bio Inc (NASDAQ: MBIO) are skyrocketing to their highest level in about a year Thursday morning.

Market Watch - 1 year ago

Shares of Mustang Bio Inc. blasted off to a near 4-fold gain (up 257%) in premarket trade Thursday.

About MBIO

Mustang Bio, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficien... [Read more...]

Industry
Biotechnology
Stock Exchange
NASDAQ
Ticker Symbol
MBIO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Mustang Bio stock is "Strong Buy." The 12-month stock price forecast is 10.75, which is an increase of 118.05% from the latest price.

Price Target
$10.75
(118.05% upside)
Analyst Consensus: Strong Buy